Advanced Medical Solutions: another PE walk-away, but the pattern matters

TA Associates this week confirmed it does not intend to proceed with a formal offer for Advanced Medical Solutions (AMS), bringing the latest private-equity approach to an end. Under Rule 2.8 of the Takeover Code, TA is now restricted from making another offer for six months — but other suitors are not.

What is striking is the pattern. Over the past 18 months alone, AMS has attracted formal interest from Inflexion (2024), Montagu Private Equity (March 2025), Bridgepoint (December 2025), and now TA Associates (April 2026). Four well-capitalised PE firms; four walk-aways; none willing to pay the price the board considers fair. Bridgepoint and TA both pitched in the 270–280p range, and management has — sensibly, in my view — held the line.

What makes AMS catnip for PE is not glamorous: a defensible niche in surgical biomaterials and wound care, recurring revenue, established European manufacturing, and — crucially — a conservatively-run balance sheet. Modest leverage after seven bolt-on acquisitions since 2019 leaves substantial unused debt capacity. For a PE buyer, that is exactly the lever that makes the IRR maths work, even on a relatively flat operational story. The same characteristic that makes AMS a measured public-market compounder makes it disproportionately attractive to financial buyers.

Operationally, FY2025 was strong: revenue £228.9m (+29%), pretax profit £17.8m (+81%), dividend up 10%. The shares have since drifted back to around 194p versus an analyst consensus target of ~276p, restoring the public-market discount that drew the PE attention in the first place.

The floor for any future bid has effectively been set at 280p. The underlying business is delivering. Past suitors will be watching closely. I remain a holder.

Disclosure: I hold a position in Advanced Medical Solutions at the time of writing. This is not investment advice — always do your own research.